In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients.
10.14701/kjhbps.2015.19.4.139
- Author:
Eunkyoung JWA
1
;
Shin HWANG
;
Yong Jae KWON
;
Nayoung KIM
;
Gi Won SONG
;
Dong Hwan JUNG
;
Chul Soo AHN
;
Eunyoung TAK
;
Deok Bog MOON
;
Ki Hun KIM
;
Tae Yong HA
;
Gil Chun PARK
;
Sung Gyu LEE
Author Information
1. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shwang@amc.seoul.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Calcineurin phosphatase;
Tacrolimus;
Rejection;
ImmuKnow;
Operational tolerance
- MeSH:
Adenosine Triphosphate;
Adult*;
Calcineurin;
Humans;
Immunosuppression*;
Liver Diseases;
Liver Transplantation;
Liver*;
T-Lymphocytes, Helper-Inducer;
Tacrolimus;
Transplantation*
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2015;19(4):139-148
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUNDS/AIMS: We evaluated the clinical usability of immune cell monitoring in adult liver transplantation (LT) recipients. METHODS: This study was composed of two parts as using calcineurin phosphatase (CNP) activity assay and ImmuKnow assay independently as in vitro monitoring tools of immune cell function in adult LT recipients. RESULTS: There was a rough correlation between CNP activity and tacrolimus concentration in 33 patients. This association was evident in patients who were only administered tacrolimus, but disappeared after the co-administration of mycophenolate. In 118 healthy individuals, the mean proportion of helper T-cells was 37.4+/-8.1%. According to ImmuKnow assay, their immune responses were strong in 12 patients (10.2%), moderate in 92 patients (78.0%), and low in 14 patients (11.9%). In 85 patients waiting for LT, there was a rough correlation between the ImmuKnow ATP level and age. Their immune responses were strong in 0 patients (0%), moderate in 8 patients (9.4%), and low in 77 patients (90.6%). There was a difference in the ImmuKnow ATP levels between healthy individuals and patients with liver disease. In 137 LT recipients, there was no correlation between the ImmuKnow ATP levels and tacrolimus concentration. This trend did not change after grouping the patients according to co-administration with mycophenolate. Eight recipients experienced acute rejection, but none showed strong immune response. CONCLUSIONS: We think that both CNP activity assay and ImmuKnow assay are too limited to objectively determine the level of immunosuppression. Further studies should be performed to identify other methods for immune function monitoring.
